Cantor Fitzgerald Starts TrovaGene (TROV) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts TROV Hot Sheet
Price: $1.19 --0%
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Cantor Fitzgerald initiated coverage on TrovaGene (NASDAQ: TROV) with a Buy rating and a price target of $10.00.
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $6.24 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Upgrades Humana (HUM) to Overweight, 'A Strong 2027 Margin Year Bridges to an Inexpensive 2028 Multiple'
- JPMorgan Resumes Trane Technologies (TT) at Overweight
- Chardan Starts Duos Technologies Group (DUOT) at Neutral
Create E-mail Alert Related Categories
New CoverageRelated Entities
Cantor FitzgeraldSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
